Unique dosing for new minocycline

May 15, 2006

The FDA has given the nod to Solodyn, the first minocycline productapproved for once-daily dosing in the treatment of inflammatorylesions of non-nodular moderate to severe acne vulgaris.Manufacturer Medicis claims that Solodyn is not bioequivalent toany other minocycline product and is the only extended-releaseminocycline in tablet form.

Unique dosing for new minocycline

The FDA has given the nod to Solodyn, the first minocycline product approved for once-daily dosing in the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. Manufacturer Medicis claims that Solodyn is not bioequivalent to any other minocycline product and is the only extended-release minocycline in tablet form. According to the company, Solodyn should be prescribed only for patients 12 years of age and older and has a unique dosage of 1 mg/kg/day. Full prescribing information can be accessed on-line at http://www.solodyn.com/.

To see more Hot off the Press news articles, click here http://www.drugtopics.com/Hot+off+the+Press.